Blood Test

This advanced lipid panel has been designed to move beyond a standard cholesterol test and provide a far more detailed, clinically meaningful assessment of cardiovascular risk.

Traditional lipid profiles offer a broad overview, but they do not fully capture how cholesterol is being transported within the bloodstream or how it behaves over time. This panel focuses on the lipoprotein particles that carry cholesterol, allowing for a more precise understanding of risk and, importantly, the underlying drivers behind any abnormalities.

At the core of the assessment is Apolipoprotein B (ApoB), which reflects the total number of atherogenic particles circulating in the blood. This is often a more accurate marker of cardiovascular risk than LDL cholesterol alone. The panel also includes Lipoprotein(a), or Lp(a), a genetically determined particle that is not routinely measured in standard tests but can significantly increase lifetime cardiovascular risk, particularly in individuals with a family history of heart disease or stroke.

In addition, the panel provides a comprehensive breakdown of cholesterol fractions, including LDL cholesterol, HDL cholesterol, non-HDL cholesterol, and triglycerides, allowing these results to be interpreted within a broader metabolic context. This is particularly important in conditions such as insulin resistance, metabolic syndrome, and familial lipid disorders, where conventional markers can be misleading.

By combining these measurements, the panel enables a more personalised and mechanistic approach to lipid management. It helps identify whether risk is driven by particle number, inherited factors, or metabolic health, and supports more targeted, evidence-based treatment decisions.

This test is particularly valuable for individuals with persistently abnormal cholesterol, a strong family history of cardiovascular disease, premature heart attack or stroke, suspected familial hypercholesterolaemia, elevated triglycerides, or those who have struggled with standard treatments such as statins.

The result is a clearer, more nuanced picture of cardiovascular risk—providing the foundation for tailored prevention strategies aimed at reducing long-term risk in a precise and informed way.